Abstract |
Numerous studies have documented that lncRNA plays a key role in
tumorigenesis and tumor progression. In particular, abnormal lncRNA
expression may accompany DNA damage, immune escape as well as cellular
metabolic disorders in cancer cells. The di versity and heterogeneity of
lncRNAs make the complicated tumorigenesis process even more intriguing.
In addition, lncRNA is also strongly associated with EMT, as well as the
regulation of cell stemness. These findings together make lncRNA a solid
compone nt of tumor metastasis. Therefore, targeting lncRNA could be an
opportune clinical approach in cancer treatment.
Combination therapy has made great progress in the clinical treatment
of tumors. Combining surgery with chemotherapy, or the emergence of
spec ific targeted drugs, has further improved the survival rate of patients.
Recently, with the significant clinical achievements in immunotherapy of
PD1/PD L1, ideas focusing on the re stimulation of the suppressed cellular
immunity of patients through immuno therapy have been under the limelight of
cancer research. As a part of the immune escape of cancer cells, lncRNAs
may provide new insight for future cancer treatment combined with
immunotherapy.
The rapid development of a new generation of gene editing tools
makes it possible to target lncRNA inside tumor cells. ASOs or CRISPR/
Cas9 based therapy has already shown the feasibility of gene editing in
treating cancer, but their off target event or unstable efficiency due to the
spatiotemporal s pecificity of lncRNA should also be carefully evaluated before
further application. Moreover, the combination of nanotechnology and
bioinformatics accelerates new nanoparticle development as well as its
optimization under clinical conditions via the deep a nalysis of lncRNA
functions and distribution. The emergence of new cancer therapeutic
strategies worldwide exhibits promise in the treatment of cancer, one of the
most serious hum an diseases.
|